SNDX · Syndax Pharmaceuticals, Inc. · Stock research

Current Thesis

The leg described here in July had two halves: a two-drug commercial ramp compounding quarter over quarter, and a frontline AML label expansion stacked on top of it. The first half has now been marked down twice by the sell side's own numbers. Q2 2026, reported 2026-08-04, produced revenue of $72.788M against a $79.323M consensus and EPS of $(0.55) against $(0.49). Four covering firms cut targets in the seventeen sessions that followed — BofA $29→$26 (2026-08-05), HC Wainwright $40→$38 (2026-08-05), JP Morgan $44→$40 (2026-08-11), UBS to $33 (2026-08-21) — and not one changed its rating. Price followed: the 2026-08-21 weekly close of $19.65 sits under the $20 shelf that had held since June and 21.9% below the 52-week high of $25.15. What remains unbought is the undated half — EVOLVE-2 Phase 3 topline in newly diagnosed NPM1m/KMT2Ar AML, guided to 2H 2026 with no calendar date attached.

The narrative is saturated. The dates that mark it are 2026-08-04 (second consecutive quarter under consensus) and the 2026-08-05 → 2026-08-21 run of target reductions into unanimous Buy/Overweight ratings while the tape made lower closes through them. Coverage is dense and directionally uniform; a marginal new buyer for the commercial-ramp story is not visible in price. dead is not the label yet, because the Phase 3 that carries most of the disputed value has not been tested.

Bullish and bearish views on Syndax Pharmaceuticals, Inc.

The model's bull view on Syndax Pharmaceuticals, Inc. (SNDX), in brief: Revenue still compounds fast off the miss: Q2 2026 total revenue $72.8M, +92% YoY, with Revuforj net revenue $54.7M (+91% YoY) and Niktimvo collaboration revenue $18.1M (2026-08-04 release). The bear view: BofA put arithmetic on the 2026-08-04 miss the next day: revenue $6M below consensus, EPS $0.08 short, Revuforj $5M under expectation, and a repeat of the Q1 pattern. Both cases follow in full.

Bull Case

• Revenue still compounds fast off the miss: Q2 2026 total revenue $72.8M, +92% YoY, with Revuforj net revenue $54.7M (+91% YoY) and Niktimvo collaboration revenue $18.1M (2026-08-04 release).
• Niktimvo in-market net sales were $60.3M in Q2 2026, +67% YoY; Syndax books 50% of net commercial profit under the Incyte collaboration.
• Operating leverage is showing: net loss $49.4M in Q2 2026 against $71.8M a year earlier, with SG&A down to $41.5M from $43.8M.
• Cash, equivalents and investments of $575.1M at 2026-06-30, including $244M net proceeds from the $250M convertible, span the guided 2H 2026 frontline readouts and the 2027 pipeline starts (INFERRED from the balance and the guided milestone dates; the release carried no runway date).
• The frontline argument rests on reported data: BEAT AML, published in the Journal of Clinical Oncology and presented at EHA 2025, showed a 67% CR rate, 88% ORR and MRD negativity in 100% of responders among newly diagnosed older adults with mNPM1 or KMT2Ar AML.
• Every firm that cut a target kept its rating; the surviving published range runs from BofA's $26 to JP Morgan's $40 against the 2026-08-21 close of $19.65.
• Pipeline extends past the two commercial assets: SNDX-4321 (mutant-selective allosteric EGFR inhibitor, NSCLC) IND guided to Q4 2026; SNDX-62122, a next-generation menin inhibitor in myelofibrosis, IND and Phase 1 start guided to 2027.

Bear Case

• BofA put arithmetic on the 2026-08-04 miss the next day: revenue $6M below consensus, EPS $0.08 short, Revuforj $5M under expectation, and a repeat of the Q1 pattern. The firm wrote that the menin class "has not yet met initial expectations" and called the NPM1m market "competitive with less urgency to treat."
• The reductions did not stop with the print. UBS came down to $33 on 2026-08-21, seventeen days after the report, with no fresh company disclosure in between to explain it.
• R&D expense rose to $68.0M in Q2 2026 from $62.2M a year earlier while the top line missed.
• The $250M convertible was placed into the stronger part of the tape and sits as equity-linked supply above its conversion price; convertible issuance typically brings arbitrage hedging that adds mechanically to borrow demand (INFERRED — no dated short-interest figure is cited here).
• Between 2026-08-04 and an unspecified 2H 2026 EVOLVE-2 topline there is no company-scheduled event capable of repricing the equity. The 2026-07-14 R&D Day passed without a break of the $25.15 high, and the base beneath it has since given way.
• The $20 structural line published here on 2026-08-09 registered on the weekly close of 2026-08-21 at $19.65.

Setup & Price Structure

Reference close 2026-08-21: $19.65 — 21.9% below the 52-week high of $25.15 and below the 2026-08-07 close of $20.40. The three-month price change is -1.5%, so most of the distance from the highs predates the Q2 print; what August added was the loss of the June–July shelf rather than a fresh vertical decline. RSI(14) at 53.4 is mid-range: no oversold reading, no momentum thrust (MEASURED: the readings. INFERRED: that the slide has been orderly, since a neutral 14-day reading at a lower price implies the tape has been chopping).

Crowding and positioning, as observables rather than a verdict: four price-target reductions between 2026-08-05 and 2026-08-21 with zero rating changes, leaving a $26-to-$40 published spread among firms that all still carry a buy-equivalent; a $250M convertible on the 2026-06-30 balance sheet as equity-linked supply; routine inducement grants for up to 59,250 shares to five new employees disclosed 2026-08-05, with no new equity offering announced since the convertible; and no earnings date inside 30 days, so nothing in the current setup is a run into a print.

Catalyst Calendar (next 30 days)

• 2026-09-09 to 2026-09-12 — SOHO 2026, the Society of Hematologic Oncology's fourteenth annual meeting, George R. Brown Convention Center, Houston. Syndax guided BEAT AML, SAVE and intensive-chemotherapy combination datasets to 2H 2026 medical meetings without naming venues; whether any of them lands here is unconfirmed as of this writing.
• ~2026-11-05 (est.) — Q3 2026 results, on the 2026-05-04 / 2026-08-04 cadence. Outside the 30-day window, and the next company-scheduled item of any kind.
• 2H 2026, undated — EVOLVE-2 Phase 3 topline. It can print on any session in the window; no date has been calendared, so it is a standing overhang rather than a scheduled catalyst.

What Would Change Our Mind

The $20 line has already done its work: it broke on the weekly close of 2026-08-21 at $19.65, which is why the ramp half of the thesis is treated above as marked down rather than pending. The next structural line beneath it is $18 — a weekly close below $18 would mean both post-print closes on record here ($20.40 on 2026-08-07, $19.65 on 2026-08-21) have been surrendered, leaving the equity marked on the $575.1M cash line plus an untested Phase 3. A secondary break, independent of price: EVOLVE-2 topline guidance moving from 2H 2026 to 2027 at the Q3 print (~2026-11-05, est.), which would strand the name without a dated event into next year.

Conditions that would argue the other way, with equal specificity: a weekly close back above $20.40 that reclaims the broken June–July shelf; Revuforj net product revenue above street at the Q3 print after two consecutive shortfalls; or an EVOLVE-2 topline release stating a statistically significant benefit on the primary endpoint against venetoclax/azacitidine, which reprices the frontline pool regardless of the launch slope. Absent one of those, the 2026-08-05 characterisation of the class by BofA is the governing datapoint on the tape.

Correlation Notes

• Incyte (INCY): Niktimvo is co-commercialised; the $60.3M Q2 2026 in-market net sales figure runs through both companies' disclosures, so Incyte's quarterly print carries the same franchise line.
• Competing menin inhibitors: BofA's 2026-08-05 note frames NPM1m as competitive with less urgency to treat; share commentary from a rival menin programme at a 2H 2026 hematology meeting reads directly against Revuforj's slope.
• Royalty Pharma: the royalty-interest financing sits ahead of equity in Revuforj economics, so incremental revenue is shared before it reaches shareholders.
• AbbVie / standard of care: venetoclax + azacitidine is the comparator in EVOLVE-2, which makes the readout a relative-efficacy event rather than a single-arm response event.
• Sector beta: an unprofitable commercial-stage biotech trades with the small-cap biotech complex and with rate expectations; no dated correlation coefficient is cited here.